182 related articles for article (PubMed ID: 29032188)
1. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T; Montironi R; Lopez-Beltran A; Van Leenders G; Allory Y; De Ridder D; Claessens F; Kockx M; Akand M; Joniau S; Netto G; Libbrecht L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):216-227. PubMed ID: 29032188
[TBL] [Abstract][Full Text] [Related]
2. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
Passiglia F; Caglevic C; Giovannetti E; Pinto JA; Manca P; Taverna S; Listì A; Gil-Bazo I; Raez LE; Russo A; Rolfo C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):259-268. PubMed ID: 29391205
[TBL] [Abstract][Full Text] [Related]
3. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
4. Present and future of personalized medicine in adult genitourinary tumors.
Ciccarese C; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Conti A; Tortora G; Cascinu S; Montironi R
Future Oncol; 2015; 11(9):1381-8. PubMed ID: 25952784
[TBL] [Abstract][Full Text] [Related]
5. [The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas].
Compérat E; Eymerit C; Moroch J; Varinot J
Aktuelle Urol; 2018 Apr; 49(2):171-177. PubMed ID: 29587322
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy advances in uro-genital malignancies.
Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy in uropathology].
Verkarre V; Roussel H; Granier C; Tartour E; Allory Y
Ann Pathol; 2017 Feb; 37(1):90-100. PubMed ID: 28111042
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for immunotherapy in genitourinary malignancies.
Slovin SF
Urol Oncol; 2016 Apr; 34(4):205-13. PubMed ID: 25791754
[TBL] [Abstract][Full Text] [Related]
10. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
Curigliano G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy in genitourinary malignancies.
Hoffman-Censits J; Wilde L
Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
[TBL] [Abstract][Full Text] [Related]
12. Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.
Montironi R; Santoni M; Lopez-Beltran A; Cheng L; Moch H; Scarpelli M
Curr Drug Targets; 2015; 16(2):96-102. PubMed ID: 25469883
[TBL] [Abstract][Full Text] [Related]
13. Inside the 2015 ASCO Genitourinary Cancers Symposium.
Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and gene therapy for genitourinary malignancies.
Sokoloff MH; Belldegrun A
Int J Urol; 1996 Jan; 3(1 Suppl):S4-18. PubMed ID: 24304019
[No Abstract] [Full Text] [Related]
15. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.
Lee B; Hutchinson R; Wong HL; Tie J; Putoczki T; Tran B; Gibbs P; Christie M
Semin Cancer Biol; 2018 Oct; 52(Pt 2):241-252. PubMed ID: 29258858
[TBL] [Abstract][Full Text] [Related]
16. Adaptive Immunity in Genitourinary Cancers.
Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for genitourinary cancer: state of the art and new perspectives.
Cattrini C; Dellepiane C; Cavo A; Buzzatti G; Tolomeo F; Messina C; Boccardo F
Anticancer Drugs; 2016 Aug; 27(7):585-99. PubMed ID: 27183027
[TBL] [Abstract][Full Text] [Related]
18. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
19. Gene and immune-based therapies for genitourinary malignancies: current status and future prospects.
Zisman A; Pantuck AJ; Belldegrun A
Isr Med Assoc J; 2000 Jan; 2(1):33-42. PubMed ID: 10892369
[No Abstract] [Full Text] [Related]
20. Morphological and molecular backgrounds for personalized therapies in genitourinary cancers.
Montironi R; Scarpelli M; Santoni M; Lopez-Beltran A; Cheng L
Curr Drug Targets; 2015; 16(2):94-5. PubMed ID: 25668146
[No Abstract] [Full Text] [Related]
[Next] [New Search]